I. What is the management of skin and soft-tissue infections
(SSTIs) in the era of community-associated MRSA (CA-MRSA)?
SSTIs
1. For a cutaneous abscess, incision and drainage is the
primary treatment (A-II). For simple abscesses or boils,
incision and drainage alone is likely to be adequate, but
additional data are needed to further define the role of
antibiotics, if any, in this setting.
2. Antibiotic therapy is recommended for abscesses
associated with the following conditions: severe or extensive
disease (eg, involving multiple sites of infection) or rapid
progression in presence of associated cellulitis, signs and
symptoms of systemic illness, associated comorbidities or
immunosuppression, extremes of age, abscess in an area
difficult to drain (eg, face, hand, and genitalia), associated
septic phlebitis, and lack of response to incision and drainage
alone (A-III).
3. For outpatients with purulent cellulitis (eg, cellulitis
associated with purulent drainage or exudate in the absence of
a drainable abscess), empirical therapy for CA-MRSA is
recommended pending culture results. Empirical therapy for
infection due to b-hemolytic streptococci is likely to be
unnecessary (A-II). Five to 10 days of therapy is recommended
but should be individualized on the basis of the
patient’s clinical response.
4. For outpatients with nonpurulent cellulitis (eg, cellulitis
with no purulent drainage or exudate and no associated
abscess), empirical therapy for infection due to b-hemolytic
streptococci is recommended (A-II). The role of CA-MRSA is
unknown. Empirical coverage for CA-MRSA is recommended
in patients who do not respond to b-lactam therapy and may be
considered in those with systemic toxicity. Five to 10 days of
therapy is recommended but should be individualized on the
basis of the patient’s clinical response.
5. For empirical coverage of CA-MRSA in outpatients with
SSTI, oral antibiotic options include the following: clindamycin
(A-II), trimethoprim-sulfamethoxazole (TMP-SMX) (A-II),
a tetracycline (doxycycline or minocycline) (A-II), and linezolid
(A-II). If coverage for both b-hemolytic streptococci and
CA-MRSA is desired, options include the following:
clindamycin alone (A-II) or TMP-SMX or a tetracycline in
combination with a b-lactam (eg, amoxicillin) (A-II) or linezolid
alone (A-II).
6. The use of rifampin as a single agent or as adjunctive
therapy for the treatment of SSTI is not recommended (A-III).
7. For hospitalized patients with complicated SSTI (cSSTI;
defined as patients with deeper soft-tissue infections, surgical/
traumatic wound infection, major abscesses, cellulitis, and
infected ulcers and burns), in addition to surgical debridement
and broad-spectrum antibiotics, empirical therapy for
MRSA should be considered pending culture data. Options
include the following: intravenous (IV) vancomycin (A-I), oral
(PO) or IV linezolid 600 mg twice daily (A-I), daptomycin
4 mg/kg/dose IV once daily (A-I), telavancin 10 mg/kg/dose IV
once daily (A-I), and clindamycin 600 mg IV or PO 3 times
a day (A-III). A b-lactam antibiotic (eg, cefazolin) may be
considered in hospitalized patients with nonpurulent cellulitis
with modification to MRSA-active therapy if there is no clinical
response (A-II). Seven to 14 days of therapy is recommended
but should be individualized on the basis of the patient’s
clinical response.
8. Cultures from abscesses and other purulent SSTIs are
recommended in patients treated with antibiotic therapy,
patients with severe local infection or signs of systemic illness,
patients who have not responded adequately to initial treatment,
and if there is concern for a cluster or outbreak (A-III).

Quoted:
For the record, I have had multiple bouts of SSTI on my legs including a 3 day hospital stay.

Two years ago I found me a new shower buddy:
http://ts1.mm.bing.net/th?id=HN.608037575319749235&pid=1.7

I have not had so much as a pimple on my legs since. Once a week Hibiclens showers worked for me, and I do keep a gallon bottle in my bathroom.